IMD-1005
/ Affinity Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 28, 2025
Anglikang Secures Exclusive Rights to Yafei’s IMD‑1005 in China
(flcube.com)
- "The agreement grants Anglikang exclusive rights to research, develop, manufacture and commercialise the IMD‑1005 TMEAbody in China, including mainland, Hong Kong, Macau and Taiwan."
Licensing / partnership • Solid Tumor
1 to 1
Of
1
Go to page
1